

15 May 2025

TRISTEL plc ("Tristel" or the "Company" or the "Group")

CFO succession planning

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that Liz Dixon, Chief Financial Officer ("CFO"), has confirmed to the Board her intention to retire from the business on 30 June 2025.

A process to appoint a new CFO is well underway and the Board has been pleased with the quality of candidates showing an interest in the position. A further announcement will be made in due course.

Bruno Holthof, Chair of the Tristel Board, commented: "On behalf of the Company I would like to offer my thanks to Liz for her contribution to the business over the years. Liz has been involved with Tristel since July 2007 when she joined as Group Chief Accountant, before becoming Finance Director of our main trading subsidiary in August 2009, and ultimately joining the Board in June 2010. She played a critical role in securing market access to North America and has positioned Tristel very well for continued profitable growth."

Matt Sassone, Chief Executive Officer of Tristel, commented: "Since Liz joined Tristel, the company has grown considerably, and Liz has played a pivotal role in that success. In addition to supporting the operational side of the business, she has been instrumental in driving our commercial performance and built a robust, capable finance team—ensuring we are well-positioned for the continued expansion we anticipate in the years ahead.

"It has been a pleasure to work with Liz over the last nine months, and I am grateful that due to her stewardship I have joined a business with a very strong financial position, and well-funded to deliver further organic commercial growth."

Liz Dixon, Chief Financial Officer of Tristel, commented: *"Whilst I am very sad to be leaving Tristel after nearly 18 years, I do so happy in the knowledge that the business is well placed both financially and commercially for its next stage of growth under the leadership of Matt and the senior team.*

"It has been a great pleasure to have been part of an amazing UK success story, and to see Tristel establish a leading position in the global infection prevention world. I wish the incredible Tristel team the very best and am confident that they will continue to deliver to our shareholders."

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:

Tristel plc Matt Sassone, Chief Executive Officer Liz Dixon, Chief Financial Officer

Walbrook PR Ltd Paul McManus / Lianne Applegarth / Alice Woodings

Cavendish Capital Markets Ltd

Geoff Nash / Trisyia Jamaludin (Corporate Finance) Sunila de Silva (ECM) / Louise Talbot (Sales)

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the <u>Tristel</u> brand, and under the <u>Cache</u> brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Via Walbrook PR www.investors.tristel.com

Tel: 020 7933 8780 or <u>tristel@walbrookpr.com</u> Mob: 07980 541 893/ 07584 391 303/ 07407 804 654

Tel: 020 7220 0500

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <u>https://tristel.com</u>